Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/4/21 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -2.25% | +1.55% | +50.84% | +70.04% | 55.01B | |
| -1.32% | -2.71% | +34.27% | +77.57% | 54.24B | |
| +1.49% | +0.13% | -18.03% | -13.94% | 23.38B | |
| -0.57% | -4.13% | +2.34% | +387.73% | 22.57B | |
| +2.44% | +1.75% | +17.62% | -10.39% | 20.19B | |
| 0.00% | +3.00% | +27.41% | -29.52% | 17.86B | |
| -3.09% | -4.68% | +25.01% | +552.28% | 15.5B | |
| -6.69% | -5.11% | +169.13% | +304.89% | 14.2B | |
| +1.25% | +0.69% | +27.30% | +184.69% | 14.2B | |
| Average | -0.87% | -0.66% | +37.32% | +169.26% | 26.35B | |
| Weighted average by Cap. | -1.04% | -0.52% | +35.04% | +131.82% |
Employees
51
